| Item type |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2017-10-03 |
| タイトル |
|
|
タイトル |
Phase I trial of multidrug resistance-associated protein 3-derived peptide in patients with hepatocellular carcinoma |
| 言語 |
|
|
言語 |
eng |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| ID登録 |
|
|
ID登録 |
10.24517/00014271 |
|
ID登録タイプ |
JaLC |
| 著者 |
Mizukoshi, Eishiro
Nakagawa, Hidetoshi
Kitahara, Masaaki
Yamashita, Tatsuya
Arai, Kuniaki
Sunagozaka, Hajime
Iida, Noriho
Fushimi, Kazumi
Kaneko, Shuichi
|
| 著者別表示 |
水腰, 英四郎
中河, 秀俊
北原, 征明
山下, 竜也
荒井, 邦明
砂子坂, 肇
飯田, 宗穂
金子, 周一
|
| 提供者所属 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
金沢大学先進予防医学研究センター / 金沢大学医薬保健研究域医学系 |
| 書誌情報 |
Cancer Letters
巻 369,
号 1,
p. 242-249,
発行日 2015-12-01
|
| ISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
0304-3835 |
| NCID |
|
|
収録物識別子タイプ |
NCID |
|
収録物識別子 |
AA00598513 |
| DOI |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.1016/j.canlet.2015.08.020 |
| 出版者 |
|
|
出版者 |
Elsevier |
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Multidrug resistance-associated protein 3 (MRP3) is a carrier-type transport protein belonging to the ABC transporters. In this study, we investigated the safety and immunogenicity of a MRP3-derived peptide (MRP3765) as a vaccine and characterized the MRP3-specific T cell responses induced. Twelve hepatocellular carcinoma (HCC) patients treated with hepatic arterial infusion chemotherapy (HAIC) were enrolled. The MRP3-derived peptide was emulsified in incomplete Freund's adjuvant and administered via subcutaneous immunization three times weekly. No serious adverse drug reactions to the peptide vaccine were observed, and the vaccination was well tolerated. The vaccination induced MRP3-specific immunity in 72.7% of the patients. In a phenotypic analysis, the largest post-vaccinated increase in MRP3-specific T cells was due to an increase in cells with the effector memory phenotype. Among the 12 patients, one patient showed a partial response, nine showed a stable disease, and two showed a progressive disease. The median overall survival time was 14.0 months. In conclusion, the safety, effects of immune boosting, and possible prolongation of overall survival by the MRP3-derived peptide demonstrate the potential of the peptide to provide clinical benefit in HCC patients. © 2015. |
| 権利 |
|
|
権利情報 |
Copyright © Elsevier (CC-BY N ND) | Embargo Period 12 months |
| 著者版フラグ |
|
|
出版タイプ |
AM |
|
出版タイプResource |
http://purl.org/coar/version/c_ab4af688f83e57aa |
| 関連URI |
|
|
|
識別子タイプ |
URI |
|
|
関連識別子 |
http://www.elsevier.com/locate/issn/03043835 |
ME-PR-KANEKO-S-242.pdf (675.5 kB)
.png)
